Mabion SA logo

MAB - Mabion SA Share Price

PLN77 0.0  0.0%

Last Trade - 24/09/21

Small Cap
Market Cap £231.8m
Enterprise Value £221.1m
Revenue £296k
Position in Universe 114th / 793
Unlock MAB Revenue
Relative Strength (%)
1m +18.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -39.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.73 0.000 0.000 0.000 0.000 0.000 28.0 198.3 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Mabion SArevenues increased from PLN0K to PLN1.6M. Net lossdecreased 37% to PLN19.6M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflects R& DExpenses - Other decrease of 74% to PLN2.2M (expense),External Expenses - Third Parties - R&D decrease of 50% toPLN1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MAB Revenue Unlock MAB Revenue

Net Income

MAB Net Income Unlock MAB Revenue

Normalised EPS

MAB Normalised EPS Unlock MAB Revenue

PE Ratio Range

MAB PE Ratio Range Unlock MAB Revenue

Dividend Yield Range

MAB Dividend Yield Range Unlock MAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MAB EPS Forecasts Unlock MAB Revenue
Profile Summary

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated October 29, 2009
Public Since August 10, 2010
No. of Shareholders: n/a
No. of Employees: 213
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Warsaw Stock Exchange
Shares in Issue 16,161,326
Free Float (0.0%)
Eligible for
MAB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MAB
Upcoming Events for MAB
Frequently Asked Questions for Mabion SA
What is the Mabion SA share price?

As of 24/09/21, shares in Mabion SA are trading at PLN77, giving the company a market capitalisation of £231.8m. This share price information is delayed by 15 minutes.

How has the Mabion SA share price performed this year?

Shares in Mabion SA are currently trading at PLN77 and the price has moved by 0.157k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mabion SA price has moved by 96.44% over the past year.

What are the analyst and broker recommendations for Mabion SA?

Of the analysts with advisory recommendations for Mabion SA, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mabion SA is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Mabion SA next release its financial results?

Mabion SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Mabion SA dividend yield?

Mabion SA does not currently pay a dividend.

Does Mabion SA pay a dividend?

Mabion SA does not currently pay a dividend.

When does Mabion SA next pay dividends?

Mabion SA does not currently pay a dividend.

How do I buy Mabion SA shares?

To buy shares in Mabion SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mabion SA?

Shares in Mabion SA are currently trading at PLN77, giving the company a market capitalisation of £231.8m.

Where are Mabion SA shares listed? Where are Mabion SA shares listed?

Here are the trading details for Mabion SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: MAB
What kind of share is Mabion SA?

Based on an overall assessment of its quality, value and momentum, Mabion SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mabion SA share price forecast 2021?

Shares in Mabion SA are currently priced at PLN77. At that level they are trading at 54.35% premium to the analyst consensus target price of 0.00.

Analysts covering Mabion SA currently have a consensus Earnings Per Share (EPS) forecast of -3.037 for the next financial year.

How can I tell whether the Mabion SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mabion SA. Over the past six months, the relative strength of its shares against the market has been -18.84%. At the current price of PLN77, shares in Mabion SA are trading at 37.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mabion SA PE Ratio?

We were not able to find PE ratio data for Mabion SA.

Who are the key directors of Mabion SA?

Mabion SA's management team is headed by:

Maciej Wieczorek - VSU
Slawomir Jaros - MGB
David James - IND
Robert Konski - IND
Dirk Kreder - PRE
Jozef Banach - SUB
Grzegorz Grabowicz - MGB
Jolanta Baranowska - CAO
Slawomir Kosciak - SUB
Zofia Szewczuk - SUB
Who are the major shareholders of Mabion SA?

Here are the top five shareholders of Mabion SA based on the size of their shareholding:

Twiti Investments, Ltd. Corporation
Percentage owned: 16.55% (2.67m shares)
Generali PTE S.A. Pension Fund
Percentage owned: 10.61% (1.71m shares)
Investors Towarzystwo Funduszy Inwestycyjnych S.A. Investment Advisor
Percentage owned: 9.3% (1.50m shares)
Polfarmex S.A. Corporation
Percentage owned: 9.12% (1.47m shares)
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. Pension Fund
Percentage owned: 9.08% (1.47m shares)
Similar to MAB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.